# A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

> **NCT06361927** · PHASE2 · UNKNOWN · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** SSGJ-707

## Key facts

- **NCT ID:** NCT06361927
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-05-15
- **Primary completion:** 2025-06
- **Final completion:** 2025-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06361927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06361927, "A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06361927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*